Dance Biopharm has announced the appointment of former Dynavax chief medical officer and president J. Tyler Martin as President, a newly created position. Martin has also been appointed a member of the board of directors. From 2003-2006, Martin was a vice president of Chiron, where he worked on the development of Tobi tobramycin inhalation powder.
Dance Chairman and Chief Executive John Patton commented, “We are very pleased to have Tyler join our team, as he has a depth of drug development experience and corporate leadership to draw from, which will be key as we develop our company’s infrastructure ahead of Phase 3 clinical trials for our inhaled insulin product.”
Martin said, “I did not plan to return to a full time in-house corporate position so soon, but this opportunity with Dance is one I could not pass up given the characteristics of Dance’s inhaled insulin product and the prospect of making an important contribution to the treatment of diabetes. I look forward to working with John Patton, a pioneer in the development of inhaled insulin, and the team at Dance to expedite this exciting product through pivotal clinical trials and ultimately to patients.”
In August 2013, Dance reported positive results from a Phase 1/2 study of its insulin formulation, which is delivered via an Aerogen handheld vibrating mesh nebulizer. In October of that year, Dance announced that it had partnered with Harmony Asset for development of the product in Asia. The company has previously referred to its inhaled insulin product as “Adagio” but is now referring to it as Dance 501.
Read the Dance Biopharm press release.
